IPSCCentury Therapeutics, Inc.vs its industry peers
A metric-by-metric comparison of Century Therapeutics, Inc. against SIC 2836 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Empresa | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IPSCEsta | $356M#4 | — | 1.3x#1 | 3.3x#1 | 1556.8%#1 | 92.4%#1 | -15.8%#1 | -3.6%#1 | -7.9%#1 | — | 272.7%#1 | — |
| AURA | $727M#1 | — | 6.8x#5 | — | — | -22.2%#4 | — | -99.0%#5 | — | — | 4.2%#4 | — |
| OCGN | $427M#2 | — | 73.5x#6 | 96.7x#3 | 8.8%#3 | -25.9%#5 | -1425.7%#3 | -1171.4%#6 | — | — | 27.2%#3 | — |
| XFOR | $385M#3 | — | 2.3x#3 | 11.0x#2 | 1273.2%#2 | -111.5%#6 | -247.4%#2 | -47.0%#4 | -1421.5%#2 | — | — | — |
| PALI | $335M#5 | 16.1x#1 | 2.6x#4 | — | — | -16.2%#3 | — | -13.2%#2 | — | — | 83.8%#2 | — |
| LXEO | $329M#6 | — | 1.4x#2 | 503.1x#4 | — | -1.7%#2 | -16706.0%#4 | -43.2%#3 | — | — | -9.1%#5 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2836). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. Esta tabla agotó el tiempo durante su construcción, por lo que cubre parte del grupo; los rangos son solo dentro de las filas mostradas y se completará en breve. Table built 2026-08-04.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice